My experience has been closer to $400 million pre approval. But this is not the norm if a platform for all solid tumors is factored in. I can hope the delay in this publication is due to the inclusion as to why this will be capable for all solid cancers, operable and inoperable, and not just the test results. It should be all about the platform.
Market Data 
Markets 
AI
